Comment on "Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors"

Drug Saf. 2018 Nov;41(11):1097-1099. doi: 10.1007/s40264-018-0702-y.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticholesteremic Agents
  • Cholesterol, LDL*
  • Humans
  • Proprotein Convertase 9*

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9